Common Contracts
3 similar Agreement and Plan of Merger contracts by Alkermes Plc., Amag Pharmaceuticals Inc.
EX-2.1 2 a18-41531_1ex2d1.htm EX-2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER BY AND AMONG AMAG PHARMACEUTICALS, INC. MAGELLAN MERGER SUB, INC., PEROSPHERE PHARMACEUTICALS INC. AND BRYAN E. LAULICHT, AS COMPANY EQUITYHOLDER REPRESENTATIVE Dated...Agreement and Plan of Merger • May 5th, 2020 • Delaware
This Agreement and Plan of Merger (this “Agreement”) is made and entered into as of December 12, 2018 by and among AMAG Pharmaceuticals, Inc., a Delaware corporation (the “Buyer”), Magellan Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Buyer (“Merger Sub”), Perosphere Pharmaceuticals Inc., a Delaware corporation (the “Company”), and Bryan E. Laulicht (the “Company Equityholder Representative”).
AGREEMENT AND PLAN OF MERGER BY AND AMONG ALKERMES, INC., THINKER MERGER SUB, INC., ALKERMES PLC, RODIN THERAPEUTICS, INC. AND SHAREHOLDER REPRESENTATIVE SERVICES LLC, AS COMPANY EQUITYHOLDER REPRESENTATIVE Dated as of November 14, 2019Agreement and Plan of Merger • November 25th, 2019 • Alkermes Plc. • Pharmaceutical preparations • Delaware
This Agreement and Plan of Merger (this “Agreement”) is made and entered into as of November 14, 2019 by and among Alkermes, Inc., a Pennsylvania corporation (the “Buyer”), Thinker Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Buyer (“Merger Sub”), Rodin Therapeutics, Inc., a Delaware corporation (the “Company”), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as representative, agent and attorney-in-fact of the Company Equityholders (the “Company Equityholder Representative”), and, solely for purposes of being bound by Section 10.16, Alkermes plc, an Irish company (“Parent”).
AGREEMENT AND PLAN OF MERGER BY AND AMONG AMAG PHARMACEUTICALS, INC. MAGELLAN MERGER SUB, INC., PEROSPHERE PHARMACEUTICALS INC. AND BRYAN E. LAULICHT, AS COMPANY EQUITYHOLDER REPRESENTATIVE Dated as of December 12, 2018Agreement and Plan of Merger • December 13th, 2018 • Amag Pharmaceuticals Inc. • Pharmaceutical preparations • Delaware
This Agreement and Plan of Merger (this “Agreement”) is made and entered into as of December 12, 2018 by and among AMAG Pharmaceuticals, Inc., a Delaware corporation (the “Buyer”), Magellan Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Buyer (“Merger Sub”), Perosphere Pharmaceuticals Inc., a Delaware corporation (the “Company”), and Bryan E. Laulicht (the “Company Equityholder Representative”).
